Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

Early breast cancer, Cost effectiveness, Letrozole, Anastrozole, Adjuvant therapy,